Other researchers investigated the role of the gut microbiome, particularly focusing on specific bacterial species and their metabolites, in enhancing the efficacy of anti-PD-L1 antibodies immunotherapy on mouse models of CRC. This evidence concerns the gene CD274 and colorectal carcinoma.